Market Place
Sourcing Support
Amphista Presents Cryo-EM platform at SLAS Europe 2025
22 May 2025 //
GLOBENEWSWIRE
Amphista Therapeutics to present novel BRD9 degradation mechanism
20 Mar 2025 //
GLOBENEWSWIRE
Amphista Names Paul Medeiros As Chief Business Officer
13 Jan 2025 //
GLOBENEWSWIRE
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
03 Sep 2024 //
GLOBENEWSWIRE
Amphista Brd9 Degradation Mechanism: Differentiated Unveiled At Conference
23 May 2024 //
GLOBENEWSWIRE
Amphista announces data demonstrating in vivo efficacy of protein degraders
24 Jan 2024 //
GLOBENEWSWIRE
Amphista protein degraders effective against cancer in animals
24 Jan 2024 //
FIERCE BIOTECH
Amphista Achieves First Milestone in Second Discovery Programme with BMS
26 Sep 2023 //
GLOBENEWSWIRE
Amphista Achieves First Discovery Milestone in Collaboration with BMS
04 May 2023 //
PR NEWSWIRE
Amphista Expands Senior Team and Announces Appointment of Louise Modis
02 May 2023 //
PR NEWSWIRE
Dementia Discovery Fund invests in Amphista Therapeutics
13 Dec 2022 //
PRNEWSWIRE
Amphista partners with Domainex to advance drug portfolio
06 Oct 2022 //
PHARMATIMES
BMS, Merck KGa enter protein degradation race with $2.3B Amphista pact
05 May 2022 //
BIOSPACE
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
21 Sep 2021 //
PRNEWSWIRE
Amphista Therapeutics Expands Research Team by Appointing Martin O`Rourke
28 Jun 2021 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.